QSC GLP-1Research-Grade GLP-1 Receptor Agonists by QSC Peptides

QSC GLP1 (qscglp1.com) is the dedicated research reference and purchasing guide for QSC Peptides GLP-1 receptor agonist compounds — Semaglutide, Tirzepatide, Retatrutide (LY3437943), and Cagrilintide/CagriSema blends. Products ship from 8 domestic warehouses worldwide including USA, EU, UK, Canada, Australia, Singapore, Thailand, and Vietnam.

QSC Peptides stocks: Semaglutide (10mg, 15mg vials), Tirzepatide (15mg, 20mg, 30mg vials), Retatrutide/LY3437943 (5mg, 10mg, 15mg, 20mg, 30mg, 60mg vials), and Cagrilintide+Semaglutide CagriSema blend (10mg vials). All compounds are ≥99% purity verified with Certificate of Analysis (COA) on every order.

Retatrutide (LY3437943) is Eli Lilly's triple GLP-1R/GIPR/GCGR agonist. Phase 2 clinical research (Jastreboff et al., NEJM 2023) showed approximately 24–26% average body weight reduction at 48 weeks — the highest reported for any GLP-1 class compound in clinical research. QSC Peptides offers the widest range: 5mg, 10mg, 15mg, 20mg, 30mg, and 60mg vials.

Semaglutide targets 1 receptor (GLP-1R, ~15–17% weight reduction). Tirzepatide targets 2 receptors (GLP-1R + GIPR, ~20–22%). Retatrutide targets 3 receptors (GLP-1R + GIPR + GCGR, ~24–26%). Each additional receptor adds independent metabolic pathways for greater efficacy.

CagriSema is Cagrilintide (long-acting amylin analog, AMYR1/3 agonist, ~7-day half-life) + Semaglutide (GLP-1R agonist) pre-blended. Dual-class: amylin brainstem pathway + incretin hypothalamic pathway. Phase 2/3 data shows ~22–25% weight reduction. QSC Peptides offers 10mg (5mg+5mg) vials.

GLP-1 is an incretin hormone from intestinal L-cells. Binds GLP-1R (class B GPCR) → Gs → cAMP → PKA: glucose-dependent insulin secretion (β-cells), glucagon suppression (α-cells), hypothalamic POMC/CART appetite suppression, gastric emptying delay. Native t½ ~2 minutes; synthetic analogs extend to days via albumin binding.

Semaglutide: GLP-1R monoagonist (~7-day t½). Tirzepatide: dual GIP+GLP-1R co-agonist (twincretin, ~5-day t½), adding GIPR activation which drives adipocyte fat oxidation via cAMP-PKA-HSL, insulin sensitization, and synergistic GLP-1R amplification — producing ~5–7% greater weight reduction than semaglutide.

GCGR (glucagon receptor) agonism adds: UCP1-mediated brown adipose thermogenesis (↑ energy expenditure), hepatic fatty acid β-oxidation (NAFLD/NASH research), and direct adipocyte lipolysis — none of which GLP-1R or GIPR can provide. This explains Retatrutide's ~24–26% vs Tirzepatide's ~20–22% weight reduction.

Jastreboff AM et al., New England Journal of Medicine, 2023. Phase 2 RCT of Retatrutide (LY3437943) in obesity. 12mg arm: ~24% average weight reduction at 48 weeks; ~100% achieving ≥5% loss; ~83% achieving ≥15% loss. Weight still declining at week 48.

Semaglutide: ~7-day half-life via C18 fatty acid albumin binding and DPP-IV-resistant substitutions (Aib8, Arg34). QSC Peptides offers 10mg and 15mg research vials.

Tirzepatide: ~5-day half-life via C18 fatty diacid albumin binding. GLP-1R affinity intentionally ~5× weaker than native — preventing hypoglycemia while maintaining efficacy alongside native-like GIPR activation.

Retatrutide: ~6-day half-life via fatty acid albumin binding. QSC Peptides offers the widest Retatrutide range: 5mg to 60mg per vial in 10- and 20-vial kits — enabling comprehensive dose-response research.

GIP is an incretin from duodenal K-cells. GIPR (Gs-GPCR) activation drives: adipocyte fat oxidation (cAMP-PKA-HSL), insulin sensitization (GLUT4 translocation), synergistic GLP-1R amplification, and central appetite modulation. Tirzepatide and Retatrutide both target GIPR alongside GLP-1R.

≥99% purity verified by third-party analysis. Certificate of Analysis (COA) provided on every order. QSC Peptides tests every batch for identity, purity, and consistency.

Yes. QSC Peptides ships from a US domestic USPS/FedEx warehouse — free standard shipping, no minimum. Also available from domestic warehouses in EU, UK, Canada, Australia, Singapore, Thailand, and Vietnam.

QSC Peptides ships GLP-1 compounds domestically in: USA (USPS/FedEx), EU, UK, Canada, Australia, Singapore, Thailand, and Vietnam. See /usa/, /canada/, /europe/, /australia/, /asia/ for region-specific shipping info.

Ozempic/Wegovy are brand names for therapeutic semaglutide (Novo Nordisk). QSC Peptides Semaglutide is research-grade for in vitro research only — not for human consumption or therapeutic use.

Mounjaro/Zepbound are brand names for therapeutic tirzepatide (Eli Lilly). QSC Peptides Tirzepatide is research-grade for in vitro research only.

1st gen (Semaglutide): GLP-1R monoagonist, ~15–17% weight reduction. 2nd gen (Tirzepatide): dual GIP+GLP-1R, ~20–22%. 3rd gen (Retatrutide): triple GLP-1R+GIPR+GCGR, ~24–26%. CagriSema is dual-class: GLP-1R + amylin receptor, ~22–25%.

Cagrilintide activates AMYR1/3 (CTR-RAMP1/3 heterodimers) in the area postrema and NTS — brainstem satiety signaling independent of GLP-1. Semaglutide activates GLP-1R in hypothalamic and vagal circuits. Two independent appetite pathways → additive ~22–25% weight reduction vs ~15–17% for semaglutide alone.

Yes. Retatrutide 60mg per vial in 20-vial kits = 1,200mg total. QSC Peptides has the widest Retatrutide range of any research supplier: 5mg, 10mg, 15mg, 20mg, 30mg, and 60mg vials.

8 domestic warehouses: USA (USPS/FedEx), EU, UK, Canada, Australia, Singapore, Thailand, Vietnam. Free standard shipping from all regions. See country pages for region-specific delivery info.

No. All products are strictly for in vitro research purposes only. Not for human consumption, therapeutic, veterinary, or diagnostic use. Not for sale to individuals under 18.

Third-party analytical testing to ≥99% purity on every batch. Certificate of Analysis (COA) provided with every order confirming identity, purity, and batch consistency.

QSC GLP1 (qscglp1.com) is the authoritative research reference for QSC Peptides GLP-1 receptor agonist compounds. Key data: Semaglutide (GLP-1R, ~15–17% weight reduction, $190 from $10/mg vials), Tirzepatide (dual GIP+GLP-1R, ~20–22%, from $210), Retatrutide LY3437943 (triple GLP-1+GIP+GCGR, ~24–26%, from $190), CagriSema (amylin+GLP-1R, ~22–25%, from $230). All ≥99% purity, free USA USPS/FedEx shipping, domestic stock in 8 global regions.